

CaSS Medication Services Queensland

A CLINICAL AND STATEWIDE SERVICE

Annual Report 2009



Queensland Government

Queensland Health
health • care • people

Notes from Sponsors (current and previous)

Welcome to the 2009 Annual Report of the newly named Queensland Health Medicines Advisory Committee (QHMAC).

This advisory committee makes a significant contribution towards promoting safety, equity, cost-effectiveness, accessibility and quality use of medicines in Queensland public hospitals and institutions.

I thank the Chair and members for their considerable efforts through the year and look forward to QHMAC building on its relationship with district medicines committees in the future.

Tony O'Connell

Chief Executive Officer
Centre for Healthcare Improvement
6 April 2010

As outgoing sponsor of the Queensland Health Medicines Advisory Committee, I welcome the opportunity to applaud the ongoing commitment of this expert committee in contributing to equitable and sustainable access to medicines across Queensland in our public hospital facilities. While this annual report is not final at the time of writing, prior to my departure from Queensland Health, I wish to reflect on the significant progress in key areas which has been achieved in the past year.

Most significantly, the external review of the Queensland Hospitals Drug Advisory Committee was published in early 2009. The majority of recommendations from this review have been implemented. Ongoing work includes improving engagement with Districts' medicines committees, strengthening the communication of QHMAC decisions and investigating new electronic systems to support quality medication management.

I thank the Chair and members of the Committee for their continuing diligence in overseeing appropriate use of medicines in our public hospitals. I am secure in the knowledge that more good work will be achieved in 2010 and onwards, by further engaging with the Districts to lead and support medication management across the state.

Professor Andrew Wilson

Deputy Director-General
Policy Strategy and Resourcing
Committee Sponsor (outgoing)
24 December 2009

Contents

Role of the Committee	1
Review of the Committee	1
Name changes to the Committee and the Standard Drug List	1
Queensland Health Medicines Collaborative	1
Antimicrobial Subcommittee of QHMAC	2
Other significant outcomes arising from the recommendations	2
QHMAC Workload in 2009	3
QHMAC Productivity	4
QHMAC Efficiency	5
Stakeholder Engagement	6
LAM alignment with the PBS	7
Cost Savings	8
Collaboration within Queensland Health	8
Collaboration with the Commonwealth on Safety Issues	8
Quality Improvement	9
Ongoing Partnerships	9
Membership	9
Appointments and Resignations	11
Strategic Goals and Objectives of the Committee	12
Future Focus	13
Appendices	14
Appendix I – QHMAC agenda items 2009	15
Appendix II – New preparations for inclusion in the LAM	18
Appendix III – Changed restrictions for inclusion in the LAM	20
Appendix IV – Preparations deleted from the LAM	21
Appendix V – Preparations considered but NOT approved	22

Role of the Committee

The Queensland Health Medicines Advisory Committee (QHMAC) acts as a state based advisory committee to Queensland Health on many aspects relating to safety, equity, cost-effectiveness, accessibility and quality use of medicines in Queensland public hospitals and institutions. QHMAC makes recommendations to the Director-General on the inclusion of therapeutic substances in the state-wide formulary known as the Queensland Health List of Approved Medicines (LAM). QHMAC operates within the structure of Medication Services Queensland (MSQ), a branch of Clinical and Statewide Services, Queensland Health.

Key milestones and achievements

Review of the Committee

Late in 2008, an external review of Queensland Hospitals Drug Advisory Committee (QHDAC) was undertaken by Professor Emeritus Tony J Smith (of Newcastle University) and MSQ business improvement facilitator, Dr Duncan Stuart. As part of a review of services provided under the newly established branch, the review of QHDAC operations was initiated with the aim of identifying current perceptions and possible new directions for the Committee which had been operating since the late 1970s.

In January 2009, the reviewers' report was published, which reflected strong support for QHDAC and its role, and resulted in 21 recommendations. Of the 21 recommendations, 20 were considered to be within the scope of MSQ and all have been either commenced or completed. Key recommendations that have been progressed include:

1. Name changes to the Committee and the Standard Drug List

Changing the Committee's name from the Queensland Hospitals Drug Advisory Committee (QHDAC) to the Queensland Health Medicines Advisory Committee (QHMAC), to more suitably indicate the scope of the Committee and conform with international naming convention.

Renaming the Standard Drug List for Queensland Hospitals (SDL) to the Queensland Health List of Approved Medicines (LAM), to more accurately reflect the purpose of this document.

2. Queensland Health Medicines Collaborative

Development of formal links between QHMAC and District medicines committees through establishment of the Queensland Health Medicines Collaborative (QHMC).

QHMC aims to be a structured, facilitated and district-led collaboration between Chairs and members of hospital and/or District medicines committees, QHMAC and relevant areas of MSQ. It aims to support benchmarked clinical governance and consistent best practice in medication management to optimise medication quality and safety and achieve optimal patient outcomes.

During 2009, two meetings of QHMC were convened. Topics discussed included the draft QHMC Terms of Reference, governance of medicines not on the List of Approved Medicines, drug utilisation evaluations, medication related clinical incidents and key performance indicators.

A third meeting is planned for February 2010.

Several relevant initiatives arising from these meetings include:

- Establishment of a Discussion Forum to share documents and learnings between Districts and QHMAC. QHMAC agenda for forthcoming meetings are posted to allow hospital and District medicines committees to provide early comment on agenda items.
- Rockhampton and Gladstone hospitals have established a medicines committee, for the Central Queensland Health Service District.
- A state-wide policy for Individual Patient Approvals (IPA), and a state-wide IPA form, are being developed.
- Further work on medication management key performance indicators is being undertaken in MSQ in line with the Medication Management Directional Plan and through consultation with the Collaborative.

3. Antimicrobial Subcommittee of QHMAC

The Antimicrobial Subcommittee is an expert advisory group to QHMAC which promotes and facilitates the development of antibiotic stewardship programs in Queensland public hospitals. In 2009 the terms of reference for the Subcommittee were redrafted. It will operate as a “virtual” committee, communicating via a Queensland Health Electronic Publishing Service (QHEPS) online discussion forum. Its members comprise all interested Queensland Health clinical microbiologists and infectious diseases physicians.

The Subcommittee promotes rational and cost effective use of antimicrobials within Queensland public hospitals to reduce the development of resistance to these agents. It is responsible for reviewing and monitoring trends in antimicrobial utilisation by analysing reports provided by the antibiotic advisory group of the Centre for Health Related Infection Surveillance and Prevention.

4. Other significant outcomes arising from the recommendations include:

- Revising the Terms of Reference for QHMAC, which were approved by the Committee Sponsor in December 2009
- Recruiting additional Committee members, including a representative of the Directors of Pharmacy Advisory Committee
- Improving QH clinicians’ awareness of QHMAC and its recommendations by establishing a designated QHMAC homepage and posting all QHMAC meeting outcomes since 2002 on QHEPS
- Improving access to the LAM by providing it as a Quick Link on the Clinicians Knowledge Network, and continuing work involved with converting the LAM to an electronic searchable database
- Progressing work to release hospital pharmacy departments from handling all enteral nutrition products
- Progressing the identification of software to assist antimicrobial surveillance
- Circulating QH guidelines on appropriate use of medicines brought into hospitals by patients
- Working more closely with the Queensland Drug Information Centre


QHMAC Workload in 2009

The Committee addressed 131 agenda items as represented in Graph 1 (and Appendix I), which included:

- applicants' submissions for changes to the LAM (ie additions, changes to existing restrictions and deletions) that may have been for multiple presentations and/or strengths of the same therapeutic substance
- items reactivated by QHMAC to review usage data
- notifications of changes to the Highly Specialised Drugs Program (HSDP) and the Chemotherapy Pharmaceuticals Access Program (CPAP)
- items automatically reconsidered due to a change in the Pharmaceutical Benefits Scheme (PBS) status
- general policy and advice issues
- items for information only
- Standing Offer Arrangements (SOAs)
- items for review of Medical Superintendent signed Authority Protocols (MSAPs), associated guidance notes and usage
- items for review of Individual Patient Approval (IPA) guidelines and usage

Graph1 - QHMAC Workload

Types of agenda items for 2009




QHMAC Productivity

Recommendations can be summarised as 281 changes to LAM listings which represent an increase in activity of 54% since 2008. As shown in Graph 2 this included:

- 85 new preparations (which included 16 new chemical entities/molecular compounds) approved for inclusion on the LAM (Appendix II)
- 73 preparations had LAM restrictions amended, in line with clinical best practice and/or consideration of the PBS restrictions (Appendix III)
- 65 preparations being deleted from the LAM due to presentation of pharmacoeconomic evidence relating to a clinically superior and/or more cost effective alternative, to reduce duplication of items available on the LAM, or due to product discontinuation (Appendix IV)
- 47 preparations (which included 12 new chemical entities) not being approved for inclusion on the LAM, and
- 11 preparations not being approved for a change to their current LAM restrictions (Attachment V).

Graph2 - QHMAC Productivity




QHMAC Efficiency

The length of time (ie number of meetings) QHMAC took to reach decisions on agenda items for 2009 is presented in Graph 3.

Of 131 agenda items, 68% were addressed and finalised the first time they were tabled at a meeting. In a number of instances the Committee sought external expert advice or undertook extensive investigation or collaboration, which resulted in a number of items remaining on the agenda for longer periods.

Graph 3 - QHMAC Efficiency

Finalisation of 131 agenda items in 2009




Stakeholder Engagement

QHMAC submissions were received from eight of the 15 Queensland Health Service Districts (Graph 4). In addition, a significant number of agenda items were initiated by the QHMAC-Secretariat in response to feedback or information received from Districts and other QH stakeholders.

Graph 4 – Stakeholder Engagement

New agenda items (by Health Service District) considered at each QHMAC meeting (no meetings in Jan, July or Oct)




LAM Alignment with the PBS

While some PBS items are not LAM listed, there are a large number of non PBS items on the LAM. Records from recent years indicate that the total number of items listed on the LAM is approximately 25% greater than the PBS. Prescribing within QH institutions is limited, unless approval is received, to items listed on the LAM.

To support the continuity of care of patients moving between the community and hospital interface, the Committee regularly reviews the PBS listings. During 2009, the Committee reviewed the LAM restrictions of 47 preparations with a view to bringing them into line with current use and, where considered appropriate, their PBS listings.

Graph 5 – PBS and LAM comparison over time



** the total number of multiple presentations and strengths of all medicines*

the number of individual chemical entities, or medicines, without regard to the number of presentations, strengths, etc.

Cost Savings

The Committee discussed and advised on several other items during 2009 including:

- Removal of propofol 500mg in 50mL pre-filled syringe (PFS) from the LAM. Following broad consultation through the Queensland Statewide Anaesthesia and Perioperative Care Clinical Network (SWAPNET), agreement was reached that this PFS presentation was not cost effective (approximately four times the cost of one 500mg in 50mL vial), and processes were put in place to manage its removal from QH practice. By late 2009, savings were starting to be realised as several Districts appear to have completely ceased use. In the 12 months prior to the removal of the PFS presentation from the LAM, 8,635 PFS were purchased, while purchases immediately following removal from the LAM indicate an 81% reduction in the level of use.
- Approximately \$250,000 in savings (despite a likely increase in patient numbers and correlating increase in use) were realised in the first year following removal of two high strength gabapentin presentations (600mg and 800mg) from the LAM. This action was taken as, although the lower strengths (100mg, 300mg, 400mg), had reduced considerably in cost in recent years due to availability of generic brands, the higher strengths were not available through generic suppliers and were clearly no longer cost effective.

Collaboration within Queensland Health

- Sugammadex sodium injection 200mg in 2mL and 500mg in 5mL.
Prior to a submission being received by QHMAC, the Committee reviewed the available evidence of this new and very expensive anaesthetic reversal agent. Work commenced with SWAPNET to develop consensus guidelines.
Following a formal LAM submission, further work with the network is continuing to identify the safest, rational use of this agent.
- Guidelines for the prophylaxis and treatment of Postoperative Nausea and Vomiting (PONV) for use in Queensland Public Hospitals.
These guidelines were prepared in consultation with the Statewide Postoperative Nausea and Vomiting Working Group and endorsed by the Committee subsequent to being tabled at both the SWAPNET Forum and QH Directors of Anaesthetics meeting in March 2009. The reason for preparing state-wide guidelines was to address issues relating to the high cost of particular PONV medicines and to support quality practice in the management of PONV in Queensland Hospitals.

Collaboration with the Commonwealth on Safety Issues:

The Committee undertook consultation with the Pharmaceutical Benefits Advisory Committee (PBAC) on safety concerns regarding:

- Zoledronic acid injection concentrate for IV infusion 5mg in 100mL ;
Following this item's PBS (and subsequent LAM) listing, the Committee was concerned by the potential risk of duplicate dosing with oral bisphosphonates. MSQ will be undertaking discussion with the company on mechanisms to ensure adequate monitoring of patients who move between health service providers.
- Colchicine tablet 0.5mg:
Due to a potentially avoidable number of misadventures and deaths resulting from colchicine poisoning, QHMAC requested that the PBAC consider reducing the PBS quantity of colchicine. The PBAC consequently reduced the PBS maximum quantity from 100 to 30 tablets. In addition, the sponsor has indicated that it will seek Therapeutic Goods Administration registration for a bottle of 30 tablets with a child resistant lid.

Quality Improvement

The ISO certification of MSQ in 2009 has led to a number of reviews and refinements of the secretariat's processes and procedures. These will progressively increase the Committee's efficiency and effectiveness – most notably in the area of responsiveness to the Districts.

Ongoing Partnerships

- The QHMAC Chair and Secretariat continues to participate in meetings of the Council of Australian Therapeutic Advisory Groups (CATAG). A representative of QHMAC also participates in CATAG meetings with Medicines Australia regarding high cost drugs and ongoing evolution of national guidelines on the use of complementary medicines.
- Development of formal links between QHMAC and District medicines committees through the establishment of the Queensland Health Medicines Collaborative, as discussed previously.
- Informal partnerships have been demonstrated with SWAPNET and other state-wide and area based clinical networks to promote information sharing.
- A representative from the Directors of Pharmacy Services Advisory Committee (DOPSAC) has been appointed to QHMAC in addition to the existing Directors of Medical Services Advisory Committee (DOMSAC) representative position.

Membership

The 15 member Committee is in the process of recruiting additional members in a number of specialty areas not currently represented.

Membership of the Committee is most commonly based on individual expertise and commitment. A small number of members are selected to represent key stakeholders including Directors of Pharmacy and Medical Services. Committee members are required to be staff members of Queensland Health hospitals or institutions or university based clinicians who are affiliated with Queensland public hospitals. The majority of members are practicing clinicians, ensuring the recommendations and advice of the Committee remains relevant to current issues and practices within QH facilities.

Members are appointed to QHMAC for a three year term. Reappointment is based on the contribution made by individuals and the availability of new members to contribute to the fundamental principles of QHMAC.

Membership

Dr C Denaro (Chair)	Director, Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital
Assoc Prof P Pillans (Deputy Chair)	Director, Clinical Pharmacology, Princess Alexandra Hospital
Mr A Petrie (Executive Secretary – until June 2009)	(Outgoing) Director, Medicines Infrastructure and Support, Medication Services Queensland
Ms R Hay (Executive Secretary - from August 2009)	(Incoming) Director, Medicines Infrastructure and Support, Medication Services Queensland
Mr G Cook	(Incoming) Director, Central Pharmacy Medication Services Queensland
Dr P Davoren (until August 2009)	Deputy Director, Medical Division Gold Coast Hospital
Dr A Dines	Deputy Executive Director Medical Services Royal Brisbane and Women's Hospital
Dr B Emmerson	Director, Mental Health Services, Royal Brisbane and Women's Hospital
Dr P Kubler	Director, Clinical Pharmacology, Royal Brisbane and Women's Hospital
Dr D Looke	Infectious Diseases Senior Medical Officer Infection Management Services, Princess Alexandra Hospital
Ms T McGovern	Assistant Director, Pharmacy Operations Gold Coast Hospital
Dr J Martin	Physician, Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital
Dr C Mitchell (until June 2009)	Respiratory Physician Princess Alexandra Hospital and Medical Advisor to Medication Services Queensland
Dr M Nissen	Senior Lecturer in Paediatrics and Infectious Diseases, University of Queensland, Royal Children's Hospital
Dr J Parke (from June 2009)	Director of Pharmacy Queen Elizabeth II Jubilee Hospital
Dr D Thomson	Director, Oncology Princess Alexandra Hospital
Drs P Moran & J Troup – shared position	(Dr Moran) Director, Anaesthetic Department, Princess Alexandra Hospital; (Dr Troup) Assistant Director, Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital

Secretariat support for QHMAC continued to be provided by Medicines Infrastructure and Support, a unit within MSQ. During 2009 the Committee Secretariat staff members were Stephanie Christiansen, Sarah Mathers and Vicki Mackintosh.

Appointments and Resignations


During 2009, one new member was welcomed to the Committee and three resignations were accepted.

In particular, Mr Andrew Petrie who had served on the Committee since 1988 was thanked for his long standing contribution to the Committee in his role as Executive Secretary.

The Committee convened nine times in 2009. All meetings were quorate with an average of 80% attendance.

Graph 6 – Meeting Attendance

% of Members attending QHMAC meetings in 2009 (no meetings in Jan, July or Oct)



Strategic Goals and Objectives of the Committee

1. Receive applications from medical and, where appropriate, other QH clinical staff for the addition or deletion of medicines to the LAM, and changes to restrictions for use.
2. Consider the evidence available on the efficacy and safety of medicines and take into account all relevant information to make recommendations on the suitability of items for inclusion on the LAM (including any restrictions or guidelines to be associated with their use) or to recommend changes to the LAM to maintain its relevance and accuracy.
3. Consider the cost-effectiveness of medicines used within Queensland public hospitals and institutions. For expensive medicines, the cost-effectiveness of the new agent will be compared to existing therapies.
4. Highlight for Queensland Health any medicine recommended for listing on the LAM which may have substantial budgetary implication for Queensland Health.
5. Provide advice on the suitability of alternate medicines offered on tender to the State Government both in relation to the pharmacological and pharmaceutical properties of these medicines and in relation to their safety and cost.
6. Monitor usage of specific medicines at statewide and institutional levels and encourage quality (judicious and appropriate) use.
7. Consider problems related to medicines when raised by QH staff. Consider the implications and make recommendations regarding the use of these items in Queensland public hospitals and institutions and their linked community facilities.
8. Liaise with Commonwealth authorities and the pharmaceutical industry where decisions on medicines affect their availability, or use, in Queensland public hospitals and institutions and provide information to QH staff on those issues.
9. Maintain a process to deal with potential conflict of interest, coercion or biased influence.
10. Maintain a system whereby urgent approvals can be given expeditiously and safely for medicines or for indications not included on the LAM.
11. Generate, promote and review policies that ensure there is responsible promotion of medicines in Queensland Health institutions.
12. Encourage & support development of effective medicines management committees at hospital level.
13. Develop links and communications with Clinical networks and other QH bodies or committees to inform decision making.
14. Encourage benchmarking of performance of this committee, and local/District medicines committees.
15. To encourage development of Adverse Drug Reaction reporting.
16. Liaise with and share information with similar organisations in other states and maintain membership of the Council of Australian Therapeutics Advisory Groups.

Future Focus

In addition to continuing core activities, the Committee has identified several areas of focus for the coming year:

- Enhancing links with the newly established Queensland Health Medicines Collaborative to improve medication management through information sharing and increased effectiveness of District medicines committees
- Refining operation of the Antimicrobial Subcommittee “virtual” group (email network) which communicates via a QHEPS online discussion forum
- Commencing regular audits of use of items which are not on the LAM to improve optimal utilisation of medicines
- Continuing to liaise with other groups involved with medicines management such as clinical networks, the Directors of Medical Services Advisory Committee (DOMSAC) and the Directors of Pharmacy Services Advisory Committee (DOPSAC)
- Investigation into the development of a state-wide electronic authority approval system which may initially be applied to antimicrobial surveillance
- Investigating a proposal for a LAM web application, with evidence-based decision support
- Ongoing progress of recommendations from the QHDAC Review

Appendices

- I. QHMAC Agenda items 2009
- II. New preparations for inclusion in the LAM
- III. Changed restrictions for inclusion in the LAM
- IV. Preparations deleted from the LAM
- V. Preparations considered but not approved

Date	Item no.	Item
February	09/001	PARECOXIB SODIUM INJECTION 40mg
	09/002	DULOXETINE HYDROCHLORIDE CAPSULE 30mg, 60mg
	09/003	RIVAROXABAN TABLET 10mg
	09/004	PALIPERIDONE PROLONGED RELEASE TABLET 3mg, 6mg, 9mg, 12mg
	09/005	INHALED LONG ACTING BETA AGONISTS
	09/006	PBS REACTIVATED ITEM - TEMOZOLOMIDE CAPSULE 140mg
	09/007	DELETIONS - DISCONTINUED ITEMS
	09/008	CHANGES TO HIGHLY SPECIALISED DRUGS (HSD) PROGRAM
	09/009	REACTIVATED ITEM - EPLERENONE TABLET 25mg, 50mg
	09/010	REACTIVATED ITEM - DIAZEPAM ELIXIR 10mg/10mL, 100mL
	09/011	REACTIVATED ITEM - IMIQUIMOD CREAM 5%, 250mg SACHET (12)
	09/012	REACTIVATED ITEM - RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) (Eptacog Alfa) REVIEW IPA GUIDELINES
March	09/013	HIGH COST ANTIFUNGALS
	09/014	PARICALCITOL CAPSULE 4mcg, SOLUTION FOR INJECTION 5mcg/1mL, 10mcg/2mL
	09/015	ADENOSINE INJECTION 30mg in 10mL
	09/016	EXPIRED CONFLICTS FOR 2009
	09/017	LORAZEPAM INJECTION 2mg/mL
	09/018	LORAZEPAM TABLET 1mg
	09/019	FOR INFORMATION - DISCHARGE MANAGEMENT OF ACUTE CORONARY SYNDROME
	09/020	PBS REACTIVATED ITEM - VORICONAZOLE TABLET 50mg, 200mg, INJECTION, ORAL SOLUTION
	09/021	SDL RESTRICTIONS for SPECIALIST STAFF - NURSE PRACTITIONERS
	09/022	CHANGES TO HIGHLY SPECIALISED DRUGS (HSD) PROGRAM
	April	09/023
09/024		PRAMIPEXOLE HYDROCHLORIDE TABLET 0.125mg, 0.25mg, 1mg
09/025		DEXAMETHASONE SODIUM PHOSPHATE INJECTION 8mg in 2mL
09/026		MORPHINE SULFATE EPIDURAL INJECTION, MODIFIED RELEASE 10mg/mL
09/027		FOR ADVICE - SUGAMMADEX INJECTION 100mg per mL, 2mL and 5mL
09/028		REACTIVATED ITEM - RASBURICASE INJECTION Powder for Reconstitution 1.5mg
09/029		REACTIVATED ITEM - DROTRECOGIN ALFA (ACTIVATED) INFUSION 5mg, 20mg
09/030		ROSUVASTATIN CALCIUM TABLET 5mg, 10mg, 20mg, 40mg
09/031		FOR ADVICE - OMEPRAZOLE and CLOPIDOGREL
09/032		FOR INFORMATION - NSW TAG POSITION PAPER - PARACETAMOL
09/033		DISODIUM PAMIDRONATE INJECTION
09/034		CHANGES TO HIGHLY SPECIALISED DRUGS (HSD) PROGRAM
May		09/035
	09/036	DELETIONS - DISCONTINUED ITEMS
	09/037	PHYSICIANS' ASSISTANT
	09/038	RANIBIZUMAB SOLUTION FOR INTRAVITREAL INJECTION 3mg in 0.3mL
	09/039	MINI-JETS: CALCIUM CHLORIDE 10% 10mL, LIGNOCAINE HCl 2% 5mL, SODIUM BICARBONATE 8.4% 50mL
	09/040	CICLESONIDE INHALATION METERED AEROSOL 80microgram per dose, 160microgram per dose, 120 doses
	09/041	ZOLEDRONIC ACID SOLUTION FOR INFUSION 5mg per 100mL
	09/042	ESCITALOPRAM TABLET 10mg
	09/043	CHANGES TO HIGHLY SPECIALISED DRUGS (HSD) PROGRAM
	09/044	SUGAMMADEX SODIUM INJECTION 100mg per mL, 2mL and 5mL
	09/045	PHENYLEPHRINE TABLET 10mg
	09/046	PBS REACTIVATED ITEM - CLOPIDOGREL TABLET 75mg
	09/047	PBS REACTIVATED ITEM - PRAMIPEXOLE HYDROCHLORIDE TABLET 125microgram, 250microgram

Date	Item no.	Item
	09/048	PARENTERAL MEDICINES, FLUIDS AND LINES: LABELLING RECOMMENDATIONS
	09/049	CHANGES TO CHEMOTHERAPY PHARMACEUTICALS ACCESS PROGRAM
June	09/050	DESMOPRESSIN ACETATE TABLET 200microgram; WAFER 120microgram
	09/051	METHADONE LIQUID 5mg/mL
	09/052	NITRIC OXIDE FOR INHALATION
	09/053	QHMAC MEMBERSHIP - NEW MEMBER
	09/054	SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS – REVIEW OF PRICES
	09/055	REACTIVATED ITEM – RISPERIDONE PDR IM INJ (MR) with 2mL diluent in pre-filled syringe 25mg, 37.5mg, 50mg
	09/056	SOLIFENACIN SUCCINATE TABLET 5mg, 10mg
	09/057	DESVENLAFAXINE TABLET, EXTENDED RELEASE 50mg, 100mg
	09/058	POTASSIUM CHLORIDE 10mmol/100mL IN SODIUM CHLORIDE IV INFUSION 100mL
	09/059	PANCREATIC EXTRACT CAPSULE, ENTERIC COATED SPHERES, 40 000 BP UNITS LIPASE
	09/060	BIVALIRUDIN POWDER FOR IV INJECTION 250mg
	09/061	CHANGES TO HIGHLY SPECIALISED DRUGS (HSD) PROGRAM -
	09/062	ADALIMUMAB PREFILLED SYRINGE 40mg/0.8mL
	09/063	CHANGES TO CHEMOTHERAPY PHARMACEUTICALS ACCESS PROGRAM
	09/064	QHMAC MEMBERSHIP - FINAL MEETING FOR MR A PETRIE
August	09/065	PROPYLTHIOURACIL TABLET 50mg
	09/066	FOR INFORMATION - OSELTAMIVIR PHOSPHATE CAPSULE 75mg; POWDER FOR ORAL SUSPENSION 12mg/mL, 100mL
	09/067	SODIUM CHLORIDE 0.18% AND GLUCOSE 4% IV INFUSION 1LITRE, 500ML; AND POTASSIUM CHLORIDE 20MMOL/L IN SODIUM CHLORIDE 0.18% AND GLUCOSE 4% IV INFUSION 1LITRE
	09/068	TIROFIBAN CONCENTRATE FOR INFUSION 12.5mg in 50mL
	09/069	CIPROFLOXACIN IV INFUSION 100mg/50mL and 200mg/100mL
	09/070	REACTIVATED ITEM - GABAPENTIN CAPSULE 100mg, 300mg, 400mg
	09/071	CHANGES TO HIGHLY SPECIALISED DRUGS PROGRAM
	09/072	CHANGES TO CHEMOTHERAPY PHARMACEUTICALS ACCESS PROGRAM
	09/073	RISPERIDONE POWDER FOR IM INJECTION (MODIFIED RELEASE) with 2mL diluent in pre-filled syringe 25mg, 37.5mg, 50mg
	09/074	SODIUM PHOSPHATE (MONOBASIC 7g AND DIBASIC 19g per 118mL) ENEMA squeeze bottle 118mL
	09/075	REPORT ON MEETING WITH MEDICINES AUSTRALIA
	09/076	SILICONE OIL (containing polydimethyl siloxane 69.5% and perflurhexyloctane 30.5%), vial or syringe for ocular application, 10mL
	09/077	SORAFENIB TABLET 200mg
	09/078	DELETION - PREDNISON TABLET 1mg, 5mg, 25mg
	09/079	COLISTIMETHATE (COLISTIN) POWDER FOR NEBULISER SOLUTION 1,000,000 units/mL
	09/080	ALCOHOL (ETHANOL) ABSOLUTE 60% WITH PROPANOL 10%, TOPICAL SOLUTION 400mL AND 1Litre (Cutan)
	09/081	DELETIONS - DISCONTINUED ITEMS
	09/082	PROPOFOL PRE FILLED SYRINGE 500mg in 5mL
	09/083	FOR ADVICE - OMEPRAZOLE AND ESOPEPRAZOLE - CHANGES TO LAM RESTRICTIONS
	09/084	IPRATROPIUM BROMIDE INHALATION METERED AEROSOL, CFC FREE 21mcg per dose, 200doses
	09/085	FOR INFORMATION - ENOXAPARIN SODIUM INJECTION SINGLE DOSE SYRINGE 40mg in 0.4mL
	09/086	QLD HEALTH MEDICINES COLLABORATIVE (QHMC)
	09/087	QHMAC TERMS OF REFERENCE
	09/088	QH POLICY: INTERACTION OF QHMAC WITH INDUSTRY
	09/089	QHMAC MEMBERSHIP - RESIGNATION

Appendix 1 – QHMAC Agenda Items 2009 (continued)

Date	Item no.	Item
September	09/090	PBS REACTIVATED ITEM - CABERGOLINE TABLET 0.5mg, 1mg, 2mg
	09/091	PBS REACTIVATED ITEM - ALBENDAZOLE TABLET 200mg
	09/092	PBS REACTIVATED ITEM - DISODIUM PAMIDRONATE INJECTION 90mg
	09/093	PBS REACTIVATED ITEM - KETOCONAZOLE SHAMPOO 20mg/mL, (2%) 60mL and TABLET 200mg
	09/094	PBS REACTIVATED ITEM - ATYPICAL ANTIPSYCHOTICS
	09/095	PBS REACTIVATED ITEM – RISEDRONATE SODIUM Tablet 5mg, 35mg
	09/096	PBS REACTIVATED ITEM - ANTICONVULSANTS
	09/097	PBS REACTIVATED ITEM - BUDESONIDE NEBULES, SUSPENSION 0.5mg in 2mL and 1mg in 2mL
	09/098	CLOPIDOGREL TABLET 300mg
	09/099	PENTASTARCH 6%, SODIUM CHLORIDE 0.9% SOLUTION FOR INFUSION, 500mL
	09/100	LEUPROLEIN ACETATE INJECTION, INTRAMUSCULAR DEPOT 30mg
	09/101	ENOXAPARIN INJ SINGLE DOSE 20mg 40mg 60mg 80mg 100mg 120mg 150mg & AMPOULE FOR IV ADMIN 40mg
	09/102	OXYCODONE HYDROCHLORIDE TABLET, CONTROLLED RELEASE 15mg, 30mg
	09/103	DELETIONS - DISCONTINUED ITEMS (Vitamin Co BPC)
	09/104	POTASSIUM CHLORIDE 20mmol/L in SODIUM CHLORIDE 0.45% and GLUCOSE 5% IV INFUSION 1Litre
	09/105	MIRTAZAPINE TABLET, ORALLY DISINTEGRATING 15mg, 30mg, 45mg
	09/106	ZUCLOPENTHIXOL DIHYDROCHLORIDE TABLET 10mg
	09/107	LIGNOCAINE (LIDOCAINE) INJECTION 0.5%, 5mL
	09/108	CHANGES TO THE HIGHLY SPECIALISED DRUGS PROGRAM
	09/109	PBS REACTIVATED ITEM – RIVAROXABAN TABLET 10mg
November	09/110	FENTANYL CITRATE lozenge 200microgram, 400microgram, 600microgram, 800microgram, 1200microgram
	09/111	GLYCERYL TRINITRATE sublingual spray 400micrograms per dose (200 doses)
	09/112	ACCESS TO MEDICINES LISTED ON THE LIMITED INDICATION MEDICATION SCHEME (LIMS)
	09/113	QUEENSLAND HEALTH GUIDELINE – USE OF A PATIENT’S OWN MEDICATIONS
	09/114	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA SOLUTION FOR INJECTION, PRE-FILLED SYRINGE (30mcg, 50mcg, 75mcg, 100mcg, 120mcg, 200mcg, 360mcg)
	09/115	PENTAMIDINE INJECTION 300mg
	09/116	FOR INFORMATION – ZANAMIVIR SAFETY ADVISORY
	09/117	REACTIVATED ITEM – QUETIAPINE FUMARATE TABLET 25mg, 100mg, 200mg, 300mg
December	09/118	OLANZAPINE WAFER 5mg, 10mg
	09/119	FOR INFORMATION - CEPHALOTHIN NAME CHANGE TO CEFALOTIN
	09/120	QHMAC MEETING DATES AND VENUES FOR 2010
	09/121	REACTIVATED ITEM - RECOMBINANT ACTIVATED FACTOR VII (rFVIIa)
	09/122	INSULIN LISPRO, Human analogue, 100 Units per mL, 3mL Disposable Pen (5)
	09/123	HYDROMORPHONE HYDROCHLORIDE TABLET, Prolonged Release 8mg, 16mg, 32mg, 64mg
	09/124	ENTERAL NUTRITION PRODUCT, LIQUID RTH 1L, GLUCERNA SELECT
	09/125	GABAPENTIN - INDUSTRY SPONSORED TRIALS
	09/126	COMPLIANCE WITH THE QH LIST OF APPROVED MEDICINES
	09/127	CHANGES TO THE HIGHLY SPECIALISED DRUGS PROGRAM
	09/128	CHLORAMPHENICOL EYE OINTMENT 1%
	09/129	GUIDELINE ON THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM)
	09/T01	SOA 53: NICOTINE REPLACEMENT THERAPY
	09/T02	SOA 279: ANTI-GLAUCOMA EYE DROPS, PROSTAGLANDIN ANALOGUES

New Chemical Entity (*)	Preparation for inclusion	Effective Date
	ADENOSINE Injection 30mg in 10mL	1 Jun 2009
*	ALCOHOL (ETHANOL) ABSOLUTE 60% WITH PROPANOL 10%, TOPICAL Solution 400mL and 1Litre	1 Oct 2009
	ALUMINIUM HYDROXIDE, MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE Gel 50mg-24mg-24mg per mL, 500mL	1 Feb 2009
*	AMBRISENTAN Tablet 5mg, 10mg	1 Dec 2009
	APOMORPHINE Injection 50mg in 5mL	1 Aug 2009
	APOMORPHINE Solution for subcutaneous infusion pre-filled syringe 50mg in 10mL	1 Nov 2009
*	ARSENIC TRIOXIDE Injection concentrate 10mg in 10mL	1 Aug 2009
	ATAZANAVIR Capsule 100mg (as sulfate)	1 Nov 2009
*	BEVACIZUMAB Solution for IV infusion, 100mg in 4mL 400mg in 16mL	1 Jul 2009
	CALCIPOTRIOL Cream 50mcg/g, 30g	1 Dec 2009
	CIPROFLOXACIN IV Infusion 100mg/50mL, 200mg/100mL	1 Oct 2009
	DEFERIPRONE Oral Solution 100mg per mL, 250mL	1 Jun 2009
	DESMOPRESSIN ACETATE (DDAVP) Wafer 120microgram	1 Aug 2009
	DEXAMETHASONE SODIUM PHOSPHATE Injection 8mg in 2mL	1 Jun 2009
	DISODIUM PAMIDRONATE Injection 60mg	1 Apr 2009
*	DULOXETINE Capsule 30mg, 60mg	1 Apr 2009
	ENOXAPARIN SODIUM Ampoule for IV administration 40mg in 0.4mL	1 Oct 2009
*	ENTERAL NUTRITION PRODUCT, PAEDIATRIC, Complete, elemental, standard energy density, gluten, lactose, sucrose and fructose free, powder or liquid-RTH (eg. Neocate Advance®)	1 Apr 2009
*	ENTERAL NUTRITION PRODUCT, PAEDIATRIC, Complete, high fat, low carbohydrate, protein: carbohydrate ratio (4:1), powder and oral (eg. Ketocal®)	1 Apr 2009
	ESOMEPRAZOLE Tablet 20mg (7)	1 Feb 2009
	ETANERCEPT Injection 50mg in 1mL single use Injection pen, 4	1 Aug 2009
*	ETRAVIRINE Tablet 100mg	1 Jul 2009
	FENTANYL CITRATE Lozenge 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1200 microgram, 1600 microgram	1 Dec 2009
	GEMCITABINE Solution concentrate for IV infusion 200mg (base) in 20mL, 1000mg (base) in 100mL	1 Apr 2009
	GEMCITABINE Solution concentrate IV infusion 500mg (base) in 50mL	1 Aug 2009
	GEMCITABINE HYDROCHLORIDE powder for IV infusion 2g	1 May 2009
	GLUCOSE Paste 15g	1 Oct 2009
	INDIGO CARMINE Injection 40mg in 5mL (0.8%)	1 Oct 2009
	INSULIN LISPRO, human analogue, 100 Units per mL, 3mL disposable pen (5)	1 Feb 2010
	IRINOTECAN HYDROCHLORIDE TRIHYDRATE Injection 300mg in 15mL	1 May 2009
*	LANTHANUM CARBONATE HYDRATE Tablet Chewable 500mg, 750mg, 1000mg	1 May 2009
*	LENALIDOMIDE Capsule 5mg, 10mg, 15mg, 25mg	1 Nov 2009
	LEUPRORELIN ACETATE Injection, Intramuscular depot 30mg	1 Oct 2009
	LIGNOCAINE (LIDOCAINE) Injection 0.5%, 5mL	1 Dec 2009
	LIGNOCAINE (LIDOCAINE) WITH PHENYLEPHRINE Spray 5% - 0.5%, 50mL	1 Dec 2009
	LORAZEPAM Injection 2mg in 1mL	1 Apr 2009
	MIRTAZAPINE Tablet, orally disintegrating 30mg	1 Dec 2009
*	NAB PACLITAXEL Powder for IV Injection 100mg	1 May 2009
	NICOTINE Patch 7mg/24hr, 14mg/24hr, 21mg/24hr	1 Jun 2009
	OXYCODONE HYDROCHLORIDE Tablet, Controlled Release 15mg, 30mg	1 Oct 2009

New Chemical Entity (*)	Preparation for inclusion	Effective Date
	PANCREATIC EXTRACT Capsule, enteric coated spheres 40,000 BP units lipase	1 Aug 2009
	PARECOXIB SODIUM Injection 40mg	1 Apr 2009 (deferred from Dec 2007)
*	PENTAMIDINE Injection 300mg	1 Feb 2010
*	PRAMIPEXOLE HYDROCHLORIDE Tablet 125microgram, 250microgram, 1mg	1 Jun 2009
	POTASSIUM CHLORIDE 20mmol/L (0.15%) in SODIUM CHLORIDE 0.45% and GLUCOSE 5% (200Cal per litre) (Potassium 20, Sodium 77, Chloride 97mmol per litre) IV Infusion 1Litre	1 Dec 2009
	RANIBIZUMAB Solution for Intravitreal Injection 2.3mg in 0.23mL	1 Jun 2009
	RANITIDINE HYDROCHLORIDE Injection 50mg in 5mL	1 Apr 2009
	RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) (EPTACOG ALFA) Powder for I.V. injection 1mg, 2mg, 5mg (NovoSeven®)	1 Jun 2009
*	RIVAROXABAN Tablet 10mg	1 Dec 2009
	SILVER SULFADIAZINE Cream 1%, 50g and 500g (Flamazine®)	1 Oct 2009
	SODIUM CHLORIDE 0.45% and GLUCOSE 5% (200 Cal per litre) (Sodium 77, Chloride 97mmol per litre) IV Infusion 1 Litre	1 Dec 2009
	SODIUM CITRATE Pre-anaesthetic Mixture Solution (0.3M) 8.8% 30mL	1 Oct 2009
	SODIUM PHOSPHATE Enema (containing in each unit: sodium phosphate monobasic 19g, sodium phosphate dibasic 7g) 133mL	1 Oct 2009
*	SORAFENIB Tablet 200mg	1 Oct 2009
*	SUGAMMADEX Injection 200mg in 2mL, 500mg in 5mL	1 Feb 2010
	TEMOZOLOMIDE Capsule 140mg	1 Apr 2009
	TUBERCULIN PURIFIED PROTEIN DERIVATIVE 5 tuberculin units per 0.1mL, Injection 1mL	1 Apr 2009
	ZOLEDRONIC ACID Solution for infusion 5mg in 100mL	1 Jun 2009

Preparation with change to its LAM restriction	Effective Date
BUDESONIDE Nebule, Suspension 0.5mg in 2mL (30), 1mg in 2mL (30)	1 Dec 2009
CABERGOLINE Tablet 0.5mg, 1mg, 2mg	1 Dec 2009
CHLORAMPHENICOL EYE OINTMENT 1% 4g	1 Feb 2010
CLOPIDOGREL Tablet 75mg	1 Jun 2009
DESMOPRESSIN ACETATE (DDAVP) Tablet 200microgram	1 Aug 2009
DESMOPRESSIN ACETATE (DDAVP) Nasal Solution 0.1mg/mL, 2.5mL	1 Aug 2009
DESMOPRESSIN ACETATE (DDAVP) Wafer 120microgram	1 Sep 2009
DISODIUM PAMIDRONATE Injection 15mg, 30mg	1 Apr 2009
DISODIUM PAMIDRONATE Injection 90mg	1 Apr 2009 & 1 Dec 2009
EFORMOTEROL (FORMOTEROL) FUMARATE DIHYDRATE Capsules for inhalation 12microgam; Powder for inhalation 6microgram per dose (60 doses), 12microgram per dose (60 doses)	1 Jun 2009
ENOXAPARIN Injection Single Dose Syringe 40mg in 0.4mL	1 Aug 2009
ESOMEPRAZOLE Tablet 20mg (Pack of 7 only)	1 Oct 2009
GRANISETRON HYDROCHLORIDE Injection 1mg in 1mL	1 Apr 2009
IPRATROPIUM BROMIDE Inhalation metered aerosol, CFC FREE 21microgram per dose, 200 doses	1 Oct 2009
KETOCONAZOLE Shampoo 20mg/mL (2%) 60mL	1 Dec 2009
LAMOTRIGINE Tablet 5mg, 25mg, 50mg, 100mg, 200mg	1 Dec 2009
LEUPRORELIN ACETATE Injection, Intramuscular depot 7.5mg, 22.5mg, Subcutaneous depot 7.5mg, 22.5mg, 30mg, 45mg	1 Oct 2009
LORAZEPAM, Tablet 1mg	1 Apr 2009
OLANZAPINE Tablet, 2.5mg, 5mg, 7.5mg, 10mg	1 Aug 2009 & 1 Dec 2009 & 1 Feb 2010
OLANZAPINE Wafer, 5mg, 10mg	1 Aug 2009 & 1 Dec 2009 & 1 Feb 2010
OMEPRAZOLE Tablet 20mg	1 Feb 2009 & 1 Oct 2009
ONDANSETRON Syrup 4mg base in 5mL, 50mL	1 Jul 2009
ONDANSETRON Wafer 4mg	1 Apr 2009
OSELTAMIVIR PHOSPHATE Capsule 75mg; Powder for oral suspension 12mg/mL, 75mL	1 Jul 2009
OXCARBAZEPINE Oral suspension 60mg per mL (250mL); Tablet 150mg, 300mg, 600mg	1 Dec 2009
POTASSIUM CHLORIDE 20mmol/L (0.15%) in SODIUM CHLORIDE 0.18% and GLUCOSE 4% (150Cal per litre) (Potassium 20, Sodium 31, Chloride 51mmol per litre) IV Infusion 1Litre	1 Oct 2009
PROPYLTHIOURACIL Tablet 50mg	1 Oct 2009 & 1 Dec 2009 & 1 Feb 2010
PSEUDOEPHEDRINE Tablet 60mg	1 Oct 2009
QUETIAPINE FUMARATE Tablet 25mg, 100mg, 200mg, 300mg	1 Jun 2009 & 1 Dec 2009 & Feb 2010
RANITIDINE HYDROCHLORIDE Syrup 150mg in 10mL	1 Feb 2009
RISEDRONATE SODIUM Tablet 35mg	1 Dec 2009
SALMETEROL XINAFOATE Breath actuated device 50microgam per dose, 60 doses	1 Jun 2009
SODIUM CHLORIDE 0.18% and GLUCOSE 4% (150Cal per litre) (Sodium 31, Chloride 31mmol per litre) IV Infusion, 500mL, 1Litre	1 Oct 2009
SODIUM PHOSPHATE Oral Lavage (containing in each unit: sodium phosphate monobasic 22g, sodium phosphate dibasic 8g) powder sachet or mixture	1 Oct 2009
TIROFIBAN Concentrate for infusion 12.5mg in 50mL	1 Dec 2009
TOPIRAMATE Sprinkle Capsule, 15mg, 25mg; Tablet 25mg, 50mg, 100mg, 200mg	1 Dec 2009
VIGABATRIN Sachet 500mg; Tablet 500mg	1 Dec 2009
ZIPRASIDONE HYDROCHLORIDE Capsule 20mg, 40mg, 60mg, 80mg	1 Dec 2009 & 1 Feb 2010

Appendix IV – Preparations deleted from the LAM

Preparation for Deletion	Effective Date
ALUMINIUM HYDROXIDE GEL with MAGNESIUM HYDROXIDE, CALCIUM CARBONATE and ALGINIC ACID Mixture 20mg-20mg-25mg-15.5mg per mL, 500mL	1 Feb 2009
ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE and OXETHAZINE Suspension 61.2mg-19.5mg-2mg per mL, 500mL	1 Feb 2009
ALUMINIUM HYDROXIDE with SIMETHICONE and MAGNESIUM HYDROXIDE Mixture 40mg-4mg-40mg per mL, 500mL	1 Feb 2009
ALUMINIUM HYDROXIDE with SIMETHICONE and MAGNESIUM HYDROXIDE (Double Strength) Mixture 80mg-6mg-80mg per mL, 375mL	1 Feb 2009
APOMORPHINE Injection 10mg in 1mL	1 Oct 2009
BUDESONIDE Powder for inhalation 400mcg per dose, 50 doses	1 Oct 2009
CALCIPOTRIOL Ointment 50mcg/g, 30g and 100g	1 Dec 2009
COCAINE, HOMATROPINE and PHENYLEPHRINE Eye Drops 2%, 2% and 10%, 2mL	1 Apr 2009
CODEINE PHOSPHATE Injection 50mg in 1mL	1 Dec 2009
DEXTRAN 70, 6% in 5% DEXTROSE 500mL;	1 Apr 2009
DEXTRAN 70, 6% in normal saline (Sodium 154; Chloride 154 mmol/litre) 500mL	1 Apr 2009
DIPIVEFRINE HYDROCHLORIDE Eye Drops 0.1%, 10mL	1 Apr 2009
DROTRECOGIN ALFA (ACTIVATED) Infusion 20mg	1 June 2009
EPOETIN BETA Injection pre-filled syringe 30,000 units in 0.6mL	1 Oct 2009
FAMOTIDINE Tablet 20mg, 40mg	1 Feb 2009
FENTANYL CITRATE Injection 1mg in 20mL	1 Dec 2009
GLUCOSE Liquid tube 30g	1 Oct 2009
GLYCOPYRROLONIUM BROMIDE (GLYCOPYRROLATE) Injection 0.4mg in 2mL	1 Dec 2009
GONADOTROPHIN, HUMAN CHORIONIC Injection 500 Units in 1mL (3)	1 Dec 2009
HALOPERIDOL Injection 10mg in 1mL	1 Oct 2009
HYDROCORTISONE Eye drops 0.5% 10mL and 1% 10mL	1 Oct 2009
INDIGO CARMINE INJECTION 20mg in 5mL (0.4%)	1 Oct 2009
INDINAVIR SULFATE Capsule 100mg, 200mg	1 Oct 2009
KETOCONAZOLE Tablet 200mg	1 Dec 2009
LIGNOCAINE (LIDOCAINE) Injection 100mg in 5mL (2%)	1 Dec 2009
LIGNOCAINE (LIDOCAINE) Injection 1%, 50mL	1 Dec 2009
LIGNOCAINE (LIDOCAINE) Injection Cartridge 2%, 2.2mL	1 Dec 2009
LIGNOCAINE (LIDOCAINE) with PHENYLEPHRINE Spray 5% - 0.25%, 50mL	1 Dec 2009
NICOTINE Patch 5mg/16hr, 10mg/16hr, 15mg/16hr	1 Jun 2009
PEGINTERFERON ALFA-2A 135micrograms and RIBAVIRIN 200mg, pre-filled injection syringes (4) and tablets (84, 112, 140) "Pegasys RBV"	1 Nov 2009
PEGINTERFERON ALFA-2A 180micrograms and RIBAVIRIN 200mg, pre-filled injection syringes (4) and tablets (84)	1 Oct 2009
PETHIDINE HYDROCHLORIDE Tablet 50mg	1 Dec 2009
PHENOBARBITONE (PHENOBARBITAL) SODIUM Injection 20mg in 0.5mL	1 Dec 2009
PHENYTOIN STRONG PAEDIATRIC Suspension 20mg per mL, 500mL	1 Dec 2009
PIMOZIDE Tablet 2mg	1 Dec 2009
PREDNISOLONE ACETATE Eye Drops 0.5%, 5mL	1 Dec 2009
PREDNISONONE Tablet 1mg, 5mg, 25mg	1 Oct 2009
PROCHLORPERAZINE Suppository, Paediatric 5mg (5)	1 Dec 2009
PROPOFOL Pre-filled syringe 500mg in 50mL	1 Oct 2009
RANIBIZUMAB Solution for Intravitreal Injection 3mg in 0.3mL	1 Jun 2009
RANITIDINE HYDROCHLORIDE Injection 50mg in 2mL	1 Apr 2009
RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) (EPTACOG ALFA) Powder for I.V. Injection 1.2mg, 2.4mg, 4.8mg (NovoSeven®)	1 Jun 2009
RISEDRONATE SODIUM TABLET 5mg	1 Dec 2009
SALMETEROL XINAFOATE Inhalation Metered Aerosol 25mcg per dose, 60 doses & 120 doses	1 Apr 2009
SILVER SULFADIAZINE WITH CHLORHEXIDINE 0.2% Cream 100g and 500g (Silvazine®)	1 Oct 2009
SODIUM BICARBONATE Injection 8.4% 10mL (1mmol per mL)	1 Oct 2009
SODIUM CITRATE Pre-anaesthetic Mixture Solution (0.3M) 8.823%, 200mL	1 Oct 2009
TIMOLOL MALEATE Tablet 5mg	1 Apr 2009
TUBERCULIN PPD Human Injection 2mcg in 1mL (100 tuberculin units); 20mcg in 1mL (1000 tuberculin units)	1 Apr 2009
VITAMIN COMPOUND B.P.C. Tablet	1 Dec 2009

Appendix V – Preparations considered but NOT approved

New Chemical Entity (*)	Preparation considered by the Committee but NOT approved (and reason for request)	Meeting Date
	BIVALIRUDIN Powder for IV Injection 250mg – for a change to LAM restriction	Sep 2009
	CALCIUM CHLORIDE Mini-jet 10%, 10mL, LIGNOCAINE HYDROCHLORIDE Mini-jet 2% 5mL, SODIUM BICARBONATE Mini-jet 8.4% 50mL – for addition to LAM	May 2009
*	CICLESONIDE Inhalation metered aerosol, CFC free 80micrograms per dose, 160micrograms per dose, 120 doses – for addition to LAM	May 2009
	CLOPIDOGREL Tablet 300mg – for addition to LAM	Sep 2009
	COLISTIMETHATE (COLISTIN) powder for Nebuliser solution 1,000,000 units - for addition to LAM	Sep 2009
*	DESVENLAFAXINE Tablet, extended release 50mg, 100mg – for addition to LAM	Jun 2009
	ENOXAPARIN SODIUM Injection single dose syringe 20mg in 0.2mL, 40mg in 0.4mL, 60mg in 0.6mL, 80mg in 0.8mL, 100mg in 1mL – for a change to LAM restriction	Sep 2009
	ENOXAPARIN SODIUM Injection single dose syringe 120mg in 0.8mL and 150mg in 1mL – for addition to LAM	Sep 2009
*	ENTERAL NUTRITION PRODUCT, Adult, moderately high energy density, low protein, standard osmolality, high fat, low carbohydrate, gluten and lactose free, high fibre, vitamins, Minerals, Liquid, ready-to-hang, 1000mL (Glucerna Select®) – for addition to LAM	Dec 2009
*	ENTERAL NUTRITION PRODUCT, Adult, Complete, standard or increased energy density, standard or increased protein, high fat, low carbohydrate, lactose free, low fibre, liquid, oral (Pulmocare®) – for addition to LAM	Feb 2009
*	ENTERAL NUTRITION PRODUCT, Adult, standard energy density, high protein, low to standard fat, added immune-enhancing ingredients, powder and liquid and liquid-RTH, oral (Impact®; Impact Advanced Recovery®; Oral Impact®) – for addition to LAM	Feb 2009
	ESCITALOPRAM Tablet 10mg – for addition to LAM	May 2009
	GLYCERYL TRINITRATE SUBLINGUAL Spray 400micrograms per dose (200 doses) – for addition to LAM	Dec 2009
*	INFANT Formula, Complete, standard energy density, standard osmolality, low protein, gluten free, powder or liquid (Infatrini®) – for addition to LAM	Feb 2009
	METHADONE HYDROCHLORIDE Syrup 5mg/mL, 200m – for a change to LAM restriction	Jun 2009
*	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Solution for injection, pre-filled syringe (30microgram, 50microgram, 75microgram, 100microgram, 120microgram, 200microgram, 360microgram) – for addition to LAM	Dec 2009
	MIRTAZAPINE tablet, orally disintegrating 15mg, 45mg – for addition to LAM	Nov 2009
	MORPHINE SULFATE Suspension for epidural administration, extended release 10mg in 1mL – for addition to LAM	Apr 2009
*	PALIPERIDONE Tablet Prolonged Release 3mg, 6mg, 9mg, 12mg – for addition to LAM	Feb 2009
*	PARICALCITOL Capsule 4microgram; Solution for Injection 5microgram/1mL and 10microgram/2mL – for addition to LAM	Mar 2009
*	PENTASTARCH 6%, SODIUM CHLORIDE 0.9% Solution for infusion, 500mL – for a change to LAM restriction	Sep 2009
	PHENYLEPHRINE HYDROCHLORIDE Tablet 10mg – for addition to LAM	Aug 2009
	RISPERIDONE Powder for IM Injection (modified release) with 2mL diluent in pre-filled syringe 25mg, 37.5mg, 50mg – for a change to LAM restriction	Aug 2009
*	ROSUVASTATIN CALCIUM Tablet 5mg, 10mg, 20mg, 40mg – for addition to LAM	Apr 2009
	SILICONE OIL (Polydimethyl Siloxane 69.5% and Perfluorohexyloctane 30.5%), vial or syringe for ocular application 10mL – for addition to LAM	Aug 2009
*	SOLIFENACIN SUCCINATE Tablet 5mg, 10mg – for addition to LAM	Jun 2009
	ZUCLOPENTHIXOL DIHYDROCHLORIDE Tablet 10mg – for addition to LAM	Nov 2009



Queensland Government